Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous isatuximab with carfilzomib and dexamethasone in relapsed or refractory multiple myeloma
2023-508870-27-00Phase 2Authorised
- Sponsor
- Sanofi
- Start
- Jan 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of isatuximab, carfilzomib and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Sanofi. Primary endpoints: Overall response rate, Maximum observed concentration and 1 more. Planned start Jan 2023; status: authorised.
02
Drugs
isatuximabcarfilzomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-508870-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508870-27-00.